Assembly Biosciences (ASMB) Reaches New 1-Year Low at $13.13

Assembly Biosciences Inc (NASDAQ:ASMB)’s share price reached a new 52-week low on Monday . The company traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares changing hands. The stock had previously closed at $18.79.

A number of equities analysts have weighed in on the stock. BidaskClub cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 23rd. Chardan Capital reiterated a “hold” rating and set a $30.00 price objective on shares of Assembly Biosciences in a research note on Monday. Finally, Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $43.00.

The company has a market capitalization of $415.44 million, a P/E ratio of -4.09 and a beta of 1.75.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.12). The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $3.69 million. Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. As a group, sell-side analysts anticipate that Assembly Biosciences Inc will post -4.61 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its holdings in shares of Assembly Biosciences by 17.0% during the 4th quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares in the last quarter. United Services Automobile Association raised its holdings in shares of Assembly Biosciences by 1.1% during the 4th quarter. United Services Automobile Association now owns 51,764 shares of the biopharmaceutical company’s stock valued at $1,171,000 after purchasing an additional 560 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Assembly Biosciences by 0.5% during the 1st quarter. Valeo Financial Advisors LLC now owns 201,000 shares of the biopharmaceutical company’s stock valued at $3,958,000 after purchasing an additional 1,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Assembly Biosciences by 3.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock valued at $3,074,000 after purchasing an additional 3,022 shares in the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Assembly Biosciences by 15.3% during the 4th quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 3,100 shares in the last quarter. Institutional investors and hedge funds own 83.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2019/04/17/assembly-biosciences-asmb-reaches-new-1-year-low-at-13-13.html.

Assembly Biosciences Company Profile (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

See Also: What is a stock buyback?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.